相关实验视频
Updated: Jan 17, 2026

05:10
Multidisciplinary Approach to Obesity Management: A Case Report
Published on: May 30, 2025
909
开发和实施肥胖医学奖学金计划:在美国学术医学中心的经验
Zoobia W Chaudhry1, Marci Laudenslager1, Kimberly A Gudzune1,2
1Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Obesity pillars
|September 15, 2025
概括
医生 医生 医生
科学领域:
- 肥胖医学和医学教育研究.
- 奖学金计划的开发和评估.
背景情况:
- 肥胖是一种广泛,复杂的慢性疾病,医生培训不足.
- 肥胖医学奖学金计划正在出现,但缺乏详细的评估.
- 本研究详细介绍了美国学术医疗中心肥胖医学奖学金的课程开发和实施情况.
研究的目的:
- 描述一个肥胖医学奖学金的课程开发过程.
- 报告奖学金计划的实施经验和成果.
- 为结构化,基于能力的肥胖医学培训提供一个模型.
主要方法:
- 一个六步课程开发方法,以既定的肥胖医学能力和认证标准为指导.
- 内容由肥胖医学教育协作,美国肥胖医学委员会 (ABOM) 和ACGME-I要求提供.
- 在基于同学和教师反的基础上,在3年内代改进,利用各种教学和评估工具.
主要成果:
- 确定了肥胖医学的19个关键内容领域,具有多种教学方法 (教学,阅读,角色扮演,临床).
- 开发评估工具 (知识检查,迷你CEX,反) 来评估学员的进度.
- 实习生取得了能力,从事学术活动,所有毕业生通过了ABOM认证;反导致了程序的改进.
结论:
- 开发的肥胖医学奖学金课程结构化,多学科,并有效培养合格的肥胖护理提供者.
- 肥胖医学奖学金培训显示了通过教育和领导力发展来推进该领域的潜力.
相关概念视频
Obesity
1.1K
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
1.1K
Drug Dosing: Obese Patients
225
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
225
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
248
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
248
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
169
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
169

